Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA

Trial Profile

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EDITA
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.
    • 24 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.
    • 24 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top